These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12821824)

  • 1. Practical applications of viral fitness in clinical practice.
    Bates M; Wrin T; Huang W; Petropoulos C; Hellmann N
    Curr Opin Infect Dis; 2003 Feb; 16(1):11-8. PubMed ID: 12821824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.
    Buckheit RW
    Expert Opin Investig Drugs; 2004 Aug; 13(8):933-58. PubMed ID: 15268633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fitness of drug resistant HIV-1: methodology and clinical implications.
    Quiñones-Mateu ME; Arts EJ
    Drug Resist Updat; 2002 Dec; 5(6):224-33. PubMed ID: 12531179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
    Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
    J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of human immunodeficiency virus type 1 replication fitness.
    Dykes C; Demeter LM
    Clin Microbiol Rev; 2007 Oct; 20(4):550-78. PubMed ID: 17934074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of antiretroviral resistance on viral fitness.
    Nijhuis M; Deeks S; Boucher C
    Curr Opin Infect Dis; 2001 Feb; 14(1):23-8. PubMed ID: 11979111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance and replication capacity assays: clinical utility and interpretation.
    Haubrich RH
    Top HIV Med; 2004; 12(2):52-6. PubMed ID: 15184711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral phenotype and fitness.
    Andreoni M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):71-6. PubMed ID: 15646067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
    Koval CE; Dykes C; Wang J; Demeter LM
    Virology; 2006 Sep; 353(1):184-92. PubMed ID: 16797050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.
    Barbour JD; Wrin T; Grant RM; Martin JN; Segal MR; Petropoulos CJ; Deeks SG
    J Virol; 2002 Nov; 76(21):11104-12. PubMed ID: 12368352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
    Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
    JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adherence and resistance].
    Klimkait T; Vernazza P
    Ther Umsch; 2004 Oct; 61(10):631-4. PubMed ID: 15532193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
    Prado JG; Parkin NT; Clotet B; Ruiz L; Martinez-Picado J
    Clin Infect Dis; 2005 Sep; 41(5):729-37. PubMed ID: 16080097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.